Trial Profile
Open-Label, Single-Sequence, Two-Cohort Study to Evaluate the Effect of Darunavir/Cobicistat and Cobicistat on BMS-626529 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Mar 2022
Price :
$35
*
At a glance
- Drugs Fostemsavir (Primary) ; Cobicistat; Cobicistat/darunavir
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 22 Mar 2022 Results assessing drug-drug interactions (DDIs) in two open-label, single-sequence, multiple-dose studies (NCT02063360 and NCT02277600) published in the Antimicrobial Agents and Chemotherapy.
- 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
- 20 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.